AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.

Related Keywords

Japan ,China ,Massachusetts ,United States ,Amoy ,Fujian ,South Korea ,Roberto Polakiewicz ,Jiemin Luo ,Cell Signaling Technology ,Supplier Succeeding In Cancer Research ,Amoy Diagnostics Co Ltd ,Chief Scientific Officer ,Detection Kit ,General Manager ,Supplier Succeeding ,Cancer Research ,Signaling Technology ,Diagnostics ,Ncology ,Antibodies ,Ntibody ,Biotechnology ,Dancer ,Arcinoma ,Fell ,Cell Signaling ,Iagnostic ,Hc ,Life Science ,Molecular Diagnostics ,Pd L1 ,Research ,Technology ,Herapeutics ,